Ir para o conteúdo principal

MediciNova (NASDAQ: MNOV) — Perfil da empresa, notícias e dados financeiros

Logo de MediciNova
MNOV MediciNova
MediciNova primary media
Perfil da empresa

MediciNova

MediciNova (NASDAQ:MNOV) is a biopharmaceutical company primarily engaged in the development of novel therapeutic products to address the unmet medical needs in the treatment of diseases with a focus on neurology. Their operations cover a range of activities from drug development to clinical trials, aiming to bring innovative treatments to market. MediciNova's projects include work on therapies for diseases such as multiple sclerosis, chronic obstructive pulmonary disease (COPD), and amyotrophic lateral sclerosis (ALS), among others. The company's objectives revolve around leveraging its proprietary drug discovery platform to accelerate the development of these treatments, improving patient outcomes, and creating shareholder value by advancing its pipeline of potential therapies towards commercialization.

Resumo

Public USParticipação acionária
2000Ano de fundação
13Funcionários
La Jolla, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de MediciNova

  • Ibudilast (MN-166) aimed at treating progressive multiple sclerosis, demonstrating potential in reducing neurological decay.
  • MN-001 (tipelukast) targets fibrotic diseases such as idiopathic pulmonary fibrosis, showing promise in reducing fibrosis.
  • MN-029 (denibulin) focuses on combating solid tumor cancers, including efforts towards halting tumor growth.
  • MN-221 (bedoradrine) serves as a treatment for acute exacerbations of asthma, improving breathing in clinical studies.
  • MN-166 (ibudilast) also explored for its effectiveness in treating amyotrophic lateral sclerosis, potentially slowing disease progression.

equipe executiva do MediciNova

  • Yuichi IwakiCo-Founder, President, CEO & Chairman
  • Kazuko MatsudaSenior VP, Chief Medical Officer & Director
  • David H. CreanChief Business Officer
  • Jason J. KrugerCFO & Principal Financial Officer

Principais indicadores financeiros

Resultados divulgados pela MediciNova, em USD.

Cap. de mercado
69,4 mi
Receita (TTM)
920,5 mil
P/L
—
LPA (diluído, TTM)
-0.2
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da MediciNova
Fim do ano fiscalReceitaResultado operacionalLucro líquido
409,7 mil-13,3 mi-12 mi
0-12,7 mi-11 mi
1 mi-9,9 mi-8,6 mi
0-14,6 mi-14,1 mi